Company Description
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases.
The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich’s ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease.
The company was incorporated in 2017 and is based in New York, New York.
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 3, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | R. Townsend |
Contact Details
Address: 345 Park Avenue South, 6th Floor New York, New York 10010 United States | |
| Phone | 212-547-9879 |
| Website | lexeotx.com |
Stock Details
| Ticker Symbol | LXEO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001907108 |
| CUSIP Number | 52886X107 |
| ISIN Number | US52886X1072 |
| Employer ID | 85-4012572 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| R. Nolan Townsend | Chief Executive Officer and Director |
| Dr. Eric Adler M.D. | Chief Medical Officer and Head of Research |
| Jenny R. Robertson J.D. | Chief Business and Legal Officer |
| Dr. Ronald G. Crystal M.D. | Co-Founder, Chief Scientific Advisor and Member of Scientific Advisory Board |
| Rand Monaghan | Vice President of Finance |
| Dr. Jose Manuel Otero Ph.D. | Chief Technical Officer |
| Dr. Sandi See Tai M.D. | Chief Development Officer |
| Ryan McHenry | Vice President and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 19, 2024 | EFFECT | Notice of Effectiveness |
| Dec 19, 2024 | 8-K | Current Report |
| Dec 13, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Dec 10, 2024 | 144 | Filing |
| Dec 3, 2024 | EFFECT | Notice of Effectiveness |
| Dec 2, 2024 | POS AM | Post-Effective amendments for registration statement |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |